S
Sean Wharton
Researcher at University of Pennsylvania
Publications - 65
Citations - 3102
Sean Wharton is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Weight loss & Medicine. The author has an hindex of 18, co-authored 48 publications receiving 1412 citations. Previous affiliations of Sean Wharton include York University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P.H. Wilding,Rachel L. Batterham,Rachel L. Batterham,Salvatore Calanna,Melanie J. Davies,Luc Van Gaal,Ildiko Lingvay,Barbara McGowan,Julio Rosenstock,Marie T D Tran,Thomas A. Wadden,Sean Wharton,Koutaro Yokote,Niels Zeuthen,Robert F. Kushner +14 more
TL;DR: In this paper, the authors showed that adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 24 mg as an anesthetic drug.
Journal ArticleDOI
Obesity in adults: a clinical practice guideline
Sean Wharton,David C.W. Lau,Michael Vallis,Arya M. Sharma,Laurent Biertho,Denise Campbell-Scherer,Kristi B. Adamo,Angela S. Alberga,Rhonda Bell,Normand G. Boulé,Elaine Boyling,Jennifer Brown,Betty Calam,Carol Clarke,Lindsay Crowshoe,Dennis Divalentino,Mary Forhan,Yoni Freedhoff,Michel Gagner,Stephen Glazer,Cindy Grand,Michael E. Green,Margaret Hahn,Raed Hawa,Rita Henderson,Dennis Hong,Pam Hung,Ian Janssen,Kristen Jacklin,Carlene Johnson-Stoklossa,Amy Kemp,Sara F. L. Kirk,Jennifer L. Kuk,Marie-France Langlois,Scott Lear,Ashley McInnes,David Macklin,Leen Naji,Priya Manjoo,Marie-Philippe Morin,Kara Nerenberg,Ian Patton,Sue Pedersen,Leticia Pereira,Helena Piccinini-Vallis,Megha Poddar,Paul Poirier,Denis Prud'homme,Ximena Ramos Salas,Christian F. Rueda-Clausen,Shelly Russell-Mayhew,Judy Shiau,Diana Sherifali,John L. Sievenpiper,Sanjeev Sockalingam,Valerie H. Taylor,Ellen L. Toth,Laurie Twells,Richard Tytus,Shahebina Walji,Leah Walker,Sonja Wicklum +61 more
TL;DR: Obesity is a complex chronic disease in which abnormal or excess body fat (adiposity) impairs health, increases the risk of long-term medical complications and reduces lifespan.
Journal ArticleDOI
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M. O'Neil,Andreas L. Birkenfeld,Barbara McGowan,Ofri Mosenzon,Sue D. Pedersen,Sean Wharton,Charlotte Giwercman Carson,Cecilie Heerdegen Jepsen,Maria Kabisch,John P.H. Wilding +9 more
TL;DR: In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses.
Journal ArticleDOI
Barriers to obesity treatment
TL;DR: Addressing treatment barriers can save resources and increase the prospect of long-term success, and may further undermine the sense of failure, low self esteem and self efficacy already common among obese individuals.
Journal ArticleDOI
Substantial changes in epicardial fat thickness after weight loss in severely obese subjects.
TL;DR: It was shown that significant weight loss can be associated with significant reduction in the epicardial fat thickness, marker of visceral adiposity in severely obese subjects, and visceral fat decrease can be proportionally higher than overall adiposity decrease.